HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Erlotinib Hydrochloride

HCID 176871
New reaction
Print
Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
183319-69-9
Standard SMILES
C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1.Cl
InChIKey
GTTBEUCJPZQMDZ-UHFFFAOYSA-N
Molecular formula
C22H24ClN3O4
Average molar mass
429.9 g/mol
Monoisotopic mass
429.14553393

Overview

Erlotinib Hydrochloride is the hydrochloride salt of a quinazoline derivative with antineoplastic properties. Competing with adenosine triphosphate, erlotinib reversibly binds to the intracellular catalytic domain of epidermal growth factor receptor (EGFR) tyrosine kinase, thereby reversibly inhibiting EGFR phosphorylation and blocking the signal transduction events and tumorigenic effects associated with EGFR activation.

Names & identifiers

Preferred name
Erlotinib Hydrochloride
IUPAC
N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine;hydrochloride
English name
Erlotinib hydrochloride
Molecular formula
C22H24ClN3O4
Molecular weight
429.9

Names & synonyms

Erlotinib hydrochloride183319-69-9erlotinib HClTarcevaOSI-774OSI 774HCl, ErlotinibCP 35877411C erlotinibCP-358,774-01DA87705X9KHydrochloride, Erlotinib
Show more names
ErLErlotinib, Hydrochloride SaltCS-491RG-1415RO-0508231
CP-3584-(m-Ethynylanilino)-6,7-bis(2-methoxyethoxy)quinazoline monohydrochlorideCP-358774CHEBI:53509DTXSID10171412CP-358774-01NSC 718781NSC718781

Database identifiers

CAS
183319-69-9
PubChem CID
176871
DTXSID
DTXSID10171412
ChEMBL
CHEMBL1079742
UNII
DA87705X9K
EC Number
620-491-0

Properties

Computed structural properties

Topological polar surface area
74.7 Ų
Hydrogen bond donors
2
Hydrogen bond acceptors
7
Rotatable bonds
11
Heavy atoms
30
Formal charge
0
Complexity
525

Experimental & physicochemical properties

Human Drugs · 3 items

FDA approved drugs -> Active ingredient

EMA approved medicines: Human medicine

FDA approved drugs -> Active ingredient

Physicochemical properties

Melting point
223 · 223-225°C
storage temp.
-20 °C · Inert atmosphere,Store in freezer, under -20°C
solubility
Soluble in DMSO (up to 18 mg/ml with warming).
pka
pKa (25°): 5.42
form
Yellow powder.
color
White or off-white
Stability
1 year · Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 3 months.
InChI
InChI=1S/C22H23N3O4.ClH/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22;/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25);1H
InChIKey
GTTBEUCJPZQMDZ-UHFFFAOYSA-N
SMILES
C12C=C(OCCOC)C(OCCOC)=CC=1N=CN=C2NC1=CC=CC(=C1)C#C.Cl

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

GHS classification

GHS Classification · 4 items

Danger

H302 (91.7%): Harmful if swallowed [Warning Acute toxicity, oral]

P203, P261, P264, P264+P265, P270, P272, P273, P280, P301+P317, P302+P352, P305+P351+P338, P318, P321, P330, P332+P317, P333+P317, P337+P317, P362+P364, P391, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 12 reports by companies from 11 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Hazard information

Hazard Classes and CategoriesAcute Tox. 4 (91.7%)

Toxicology

Drug Induced Liver Injury · 6 items

Drug Induced Liver Injury Rank (DILIrank 2.0)

Erlotinib hydrochloride

vMost-DILI-concern

8

Warnings & precautions

DOI:10.1016/j.drudis.2016.02.015

Safety data

wgk
WGK 3
rtecs
VA0971200
hs_code
29335990
Signal word
Warning
Symbol(GHS)
GHS07
safety_code
24/25
Storage Class
11 - Combustible Solids
Hazard statements
H413
Hazard Classifications

Chemistry & industry

Pharmacology

FDA Pharmacological Classification · 2 items

ERLOTINIB HYDROCHLORIDE

Kinase Inhibitor [EPC]; Protein Kinase Inhibitors [MoA]

MeSH Pharmacological Classification · 2 items

Substances that inhibit or prevent the proliferation of NEOPLASMS.

Protein kinase inhibitors that inhibit TYROSINE PROTEIN KINASES.

Applications · 5 items

DescriptionErlotinib, launched as once daily oral treatment for patients with non-small-cell lung cancer (NSCLC), is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase, and it is the second small-molecule drug to be marketed with this mechanism of action. Both erlotinib and its predecessor, gefitinib, are members of the anilinoquinazoline class of tyrosine kinase inhibitors. They compete with the binding of ATP to the intracellular tyrosine kinase domain of EGFR, thereby inhibiting receptor autophosphorylation and blocking downstream signal transduction. Erlotinib is prepared by the condensation of 3-ethynylaniline with 4-chloro-6,7-bis(2-methoxyethoxy)quinazoline, which is a key intermediate obtained in five synthetic steps starting from ethyl 3,4- dihydroxybenzoate. In vitro, Erlotinib inhibits purified human EGFR tyrosine kinase with an IC50 of 2 nM and blocks EGFR autophosphorylation in cellular assays with an IC50 of 20nM. Treatment of human colon cancer cells with erlotinib was associated with growth inhibition, G1 cell cycle arrest, and apoptosis. Oral administration of erlotinib in athymic mice produced potent antitumor effects with an ED50 of 9.2 mg/kg/day for HN5 head and neck xenografts and 14 mg/ kg/day for A431 epidermoid xenografts. The absorption of Erlotinib following oral dosing is approximately 60%. Food greatly enhances the absorption allowing for almost 100% bioavailability of the dose. The time to reach peak plasma levels of the drug is about 4 hours, and the half-life is approximately 36 hours. Steady-state drug levels are reached in 7 to 8 days. Erlotinib has high protein binding (93%) and has an apparent volume of distribution of 232 L. It is metabolized primarily by CYP3A4 and to a lesser extent by CYP1A2 and CYP1A1. The drug is mainly excreted in the feces with less than 9% of the dose found in the urine. Erlotinib is labeled for the treatment of patients with locally advanced or metastatic NSCLC who have failed one or more previous chemotherapy regimens. The recommended dosage is 150 mg daily until disease progression is detected. In a randomized, double blind, placebo-controlled trial involving 731 patients, 150 mg/day oral dose of erlotinib resulted in a median overall survival of 6.7 months compared with 4.7 months in the placebo group (p<0.001). Progression-free survival was 9.9 weeks and 7.9 weeks in the erlotinib and placebo groups, respectively (p<0.001). Survival at one year was 31.2% in the erlotinib group versus 21.5% in the placebo group. The use of erlotinib showed greater benefit in patients with EGFR positive tumors and in those who never smoked. The most common adverse events reported in clinical trials were rash (9%) and diarrhea (6%). Elevations in liver function tests were also seen; however, these effects were mainly transient or associated with liver metastases. As previously noted for ge

Related reactions

58 records
New reaction record
HRID 238993 reaction equation
HRID 238993As product
HRID 238994 reaction equation
HRID 238994As product
HRID 238995 reaction equation
HRID 238995As product
HRID 238996 reaction equation
HRID 238996As product
HRID 238997 reaction equation
HRID 238997As product
HRID 238998 reaction equation
HRID 238998As product
HRID 239001 reaction equation
HRID 239001As product
HRID 243531 reaction equation
HRID 243531As product
PreviousPage 1 of 8

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
CAS DataBase Reference
183319 · 183319-69-9(CAS DataBase Reference)
NCI Dictionary of Cancer Terms
-358 · CP-358; 774; erlotinib hydrochloride; OSI-774
FDA UNII
87705 X9K · DA87705X9K
NCI Drug Dictionary
erlotinib hydrochloride
UNSPSC Code
41116107 · 41116107
NACRES
77 · NA.77
Symbol(GHS)
7 · GHS07
Signal word
Warning
Hazard statements
413 · H413
Precautionary statements
501 · P501-P273
Safety Statements
24 · 24/25
WGK Germany
3 · WGK 3
RTECS
971200 · VA0971200
HS Code
29335990 · 29335990
Storage Class
11 · 11 - Combustible Solids
Hazard Classifications
4 Oral · Acute Tox. 4 Oral
Acute Tox. 4 Oral
Precautionary statements
P501-P273

UsesErlotinib hydrochloride (V), a quinazoline derived small molecule inhibitor of epidermal growth factor receptor (EDGFR) tyrosine kinase, was approved in November, 2004, for the treatment of advanced or metastatic non-smallcell lung cancer. It belongs to the same class as gefitinib,another quinazoline approved for treatment of advanced lung cancer, but with improved pharmacokinetic properties. The molecule was originated by Pfizer and development initiated in collaboration with OSI, which assumed full rights to the drug when Pfizer merged with Warner Lambert. Subsequently, Genentech/Roche went into licensing agreement with OSI to develop and market the drug in the US and Worldwide.

UsesSelective epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor. Antineoplastic

UsesErlotinib HCl (OSI-744) is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl. Phase 3.

General DescriptionErlotinib is available as 25-, 100-, and 150-mg tablets fororal administration and is used after failure of first-linetherapy in metastatic NSCLC and as first-line therapy incombination with gemcitabine in the treatment of metastaticpancreatic cancer, and in treating malignant gliomas.The structural similarity to gefitnib imparts similar pharmacokineticbehavior with bioavailability of 60% and proteinbinding of 93%. The agent is extensively metabolizedprimarily by CYP3A4. Three major metabolic pathwayshave been identified, involving oxidative-O-demethylationof the side chains followed by further oxidation to give thecarboxlic acids, oxidation of the acetylene functionalityto give a carboxylic acid, and aromatic hydroxylation ofthe phenyl ring para to the electron-donating nitrogen. Themetabolites are primarily eliminated in the feces, and theterminal half-life is 36 hours.The major toxicities seenwith the agent are dose-limiting skin rash and diarrhea.Other common adverse effects include shortness of breath,fatigue, and nausea.

Upstream & downstream products

Downstream products

Erlotinib

Additional notes

DefinitionChEBI: A quinazoline hydrochloride compound having a (3-ethynylphenyl)amino group at the 4-position and two 2-methoxyethoxy groups at the 6- and 7-positions.